Jardiance Tablet, Film Coated
Product Images NDC 50090-4384

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-4384). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Jardiance 01

Chemical structure of Empagliflozin shown as a two-dimensional skeletal formula with labeled atoms including chlorine, oxygen, and hydroxyl groups, depicting the molecular framework.*

FDA Label Image

Jardiance 02

A forest plot chart showing the geometric mean ratio with 90% confidence intervals for various drugs relative to empagliflozin alone. It includes antidiabetic drugs such as Metformin, Glimepiride, Pioglitazone, Sitagliptin, and Linagliptin, as well as other drugs like Simvastatin, Warfarin, Verapamil, Ramipril, Gemfibrozil, Hydrochlorothiazide, Torsemide, Rifampicin, and Probenecid. The x-axis depicts change relative to empagliflozin alone, with measures for AUC and Cmax values for each drug.*

FDA Label Image

Jardiance 03

A forest plot showing the geometric mean ratio with 90% confidence intervals of pharmacokinetic parameters AUC and Cmax for various drugs. The drugs are grouped as antidiabetic drugs, oral contraceptives, and other medications, each listed with dose information. The plot visualizes how each drug's pharmacokinetics compare relative to a reference, with a scale ranging roughly from 50 to 150 on the x-axis.*

FDA Label Image

Jardiance 04

Line graph showing mean percentage change from baseline in HbA1c over 24 weeks. The chart compares placebo, Empagliflozin 10 mg, and Empagliflozin 25 mg groups, with the 25 mg group demonstrating the greatest reduction in HbA1c. The x-axis represents weeks (Baseline, 6, 12, 18, 24) and the y-axis represents HbA1c change percentage. Error bars are shown for Week 24 data points.*

FDA Label Image

Jardiance 05

A line graph comparing the mean percentage change in HbA1c levels from baseline over 52 weeks between two treatment groups: Glimepiride + Metformin (N=700) and Empagliflozin 25 mg + Metformin (N=693). The graph shows changes at intervals of 4, 12, 28, 40, and 52 weeks, with a side panel displaying week 52 mean treatment differences.*

FDA Label Image

Jardiance 06

A line graph comparing the percentage of patients with an event over 48 months for Placebo versus All Empagliflozin groups. The graph includes a table listing the number of subjects at risk over time intervals for both groups.*

FDA Label Image

Jardiance 07

A line graph comparing the percentage of patients with an event over 48 months between a placebo group and those taking empagliflozin. The x-axis represents time in months, and the y-axis represents the percentage of patients with the event. Below the graph is a table showing the number of subjects at risk for each group at different time points.*

FDA Label Image

Jardiance 08

FDA Label Image

Jardiance 08a

A Kaplan-Meier curve showing the estimated cumulative incidence of a clinical outcome over 810 days since randomization, comparing Empagliflozin 10 mg (dashed line) with Placebo (solid line). The graph includes patient counts at risk at multiple time points and displays a hazard ratio (HR) of 0.75 with 95% confidence interval (0.65, 0.86) and a P-value less than 0.0001, indicating statistical comparison between the two groups.*

FDA Label Image

Jardiance 08b

A Kaplan-Meier curve showing the mean number of events over days since randomization comparing Empagliflozin 10 mg (N=1863) and placebo (N=1867). The graph illustrates a lower event rate with Empagliflozin compared to placebo over approximately 810 days, with a hazard ratio (HR) of 0.70 (95% CI: 0.58 to 0.85) and a p-value of 0.0003, indicating statistical significance.*

FDA Label Image

Jardiance 08c

A forest plot comparing hazard ratios (with 95% confidence intervals) for Empagliflozin 10 mg versus placebo across various subgroups including diabetes status, age, sex, race, BMI, eGFR, NYHA class, heart failure physiology, and baseline medication use. The plot illustrates subgroup-specific hazard ratios with a central vertical line at 1 indicating no effect, and horizontal lines depicting confidence intervals.*

FDA Label Image

Label Image (Lbl500904384)

Label for Jardiance 25 mg film-coated tablets by A-S Medication Solutions. The label indicates the active ingredient empagliflozin, package size of 90 tablets, and storage instructions to keep at 68 to 77 degrees Fahrenheit. The product is an oral human prescription drug with NDC 50090-4384.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.